Stoke’s shares shoot up 90% as epilepsy drug slashes convulsive seizures

Investors are stocking up on Stoke Therapeutics, sending the biotech’s shares jumping over 90% in pre-market trading on the back of positive phase 1/2a data for a seizure disorder medicine.

The data comes from a study of the antisense oligonucleotide STK-001 in children and adolescents aged between two and 18 years with Dravet syndrome who were already taking the “best available anti-seizure medicines,” Stoke reported Monday afternoon.